ifosfamide and plerixafor

ifosfamide has been researched along with plerixafor in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D1
Athanasopoulos, A; Daladimos, T; Dimitriadis, G; Gekas, C; Kosmas, C; Lydakis, D; Magiorkinis, E; Miltiadous, C; Mylonakis, N; Zilakos, M; Ziras, N1
Craig, MD; Cumpston, A; D'Souza, A; Dhakal, B; Eastwood, D; Esselman, J; Fenske, TS; Hamadani, M; Hari, P; Kanate, AS; Pasquini, MC; Shillingburg, A; Veltri, LW; Watkins, K1

Reviews

1 review(s) available for ifosfamide and plerixafor

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for ifosfamide and plerixafor

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine

2009
Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumo
    Anti-cancer drugs, 2014, Volume: 25, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cisplatin; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Transplantation, Autologous; Young Adult

2014
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Transfusion; Carboplatin; Cyclams; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Young Adult

2016